Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Temferon,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : ENEA Tech and Biomedical
Deal Size : $21.9 million
Deal Type : Financing
Genenta Secures €20M to Expand Pipeline Amid Brain Tumor Trial Success
Details : The financing will be used to advance their pipeline product Temferon, which is being evaluated for the treatment of methastatic Renal Cell Cancer.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
March 19, 2025
Lead Product(s) : Temferon,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : ENEA Tech and Biomedical
Deal Size : $21.9 million
Deal Type : Financing
Lead Product(s) : Temferon,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : AGC Biologics
Deal Size : Undisclosed
Deal Type : Agreement
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
Details : Un der the agreement, AGC will support the Genenta to advance their pipeline product Temferon, which is being evaluated for the treatment of methastatic Renal Cell Cancer.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 09, 2025
Lead Product(s) : Temferon,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : AGC Biologics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Temferon
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Alira Health | Arithmos | Ospedale San Raffaele
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Temferon is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 04, 2024
Lead Product(s) : Temferon
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Alira Health | Arithmos | Ospedale San Raffaele
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Temferon
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
Details : Temferon is based on ex-vivo gene transfer into autologous Tie2+ HSPCs to deliver immunomodulatory molecules. It is being evaluated for metastatic renal cell cancer.
Product Name : Temferon
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 02, 2024
Lead Product(s) : Temferon
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Temferon
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Genenta Reprograms Tumor Microenvironment in GBM Patients
Details : Temferon uses ex-vivo gene transfer into autologous Tie2+ HSPCs to deliver immunomodulatory molecules via tumor-infiltrating monocytes; it's in phase 1/2 trials for uMGMT glioblastoma.
Product Name : Temferon
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 08, 2024
Lead Product(s) : Temferon
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Temferon
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
Details : Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-α expression within cancers, which is investigated for the treatment of Glioblastoma Multiforme.
Product Name : Temferon
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 28, 2023
Lead Product(s) : Temferon
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Temferon
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The European Commission Grants Orphan Drug Designation to Temferon for Treatment of Glioma
Details : Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-α expression within cancers, which is investigated for the treatment of glioma.
Product Name : Temferon
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 29, 2023
Lead Product(s) : Temferon
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Ospedale San Raffaele
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The amended and restated license agreement reinforces Genenta's long-term strategic relationship with OSR, who contributes unique and valuable expertise to the development of cell-based therapies. Genenta has exclusive worldwide commercial rights to Temf...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 03, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Ospedale San Raffaele
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Temferon
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme
Details : Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-alpha expression within cancers. Temferon modifies TEMs to release IFN-α inside tumors, rebuilding the immune system and counte...
Product Name : Temferon
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 02, 2023
Lead Product(s) : Temferon
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Temferon
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ongoing trial of Temferon™ in glioblastoma multiforme patients who have an unmethylated MGMT gene promoter has escalated to next planned dose, on basis of no drug-limiting toxicities observed at lower doses, in previous three dose level cohorts.
Product Name : Temferon
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Temferon
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable